VVUS News 4.02 09/10/2014 05:48:19 Vivus Inc (VVUS)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 6:48 AM

Vivus Inc (VVUS) 4.02 $VVUS

Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 8:45AM CDT
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech index by a full...

Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.

3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....

VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.

VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.

Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.

VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.

Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.

VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.

Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.

VIVUS Reports Second Quarter 2014 Financial Results
Marketwire - Fri Aug 08, 5:25AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing QsymiaÂ® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the second quarter ended June 30, 2014 and provided a business update.

Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:45PM CDT
Emergent BioSolutions (EBS) is set to report second quarter 2014 results on Aug 7 after the market closes.

Will Horizon Pharma (HZNP) Earnings Miss Estimates in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:00PM CDT
Horizon Pharma (HZNP) is set to report second quarter 2014 results on Aug 7 before the market opens.

Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 3:35PM CDT
Mylan (MYL) is set to report second quarter 2014 results on Aug 7 before the market opens.

Technical Analysis on Pharma Equities -- Mylan, AVANIR Pharma, Horizon Pharma, VIVUS, and Auxilium Pharma
PR Newswire - Wed Aug 06, 8:10AM CDT
On Tuesday, August 5, 2014, the NASDAQ Composite ended at 4,352.84, down 0.71%, the Dow Jones Industrial Average declined 0.84%, to finish the day at 16,429.47, and the S&P 500 closed at 1,920.21, down 0.97%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health care Sector Index ended the day at 701.26, down 0.89%, while the index has advanced 4.26% in the previous three months. Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: ANVR), Horizon Pharma Inc. (NASDAQ: HZNP), VIVUS Inc. (NASDAQ: VVUS), and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Free research on these five companies can be accessed at:

Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.

VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call
GlobeNewswire - Thu Jul 31, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results for the second quarter ended June 30, 2014 after the NASDAQ Market closes on Thursday, August 7, 2014. The company will conduct a conference call and an audio webcast at 4:30pm EDT the same day.

Vivus Shares Down 40.9% Since SmarTrend's Sell Call (VVUS)
Comtex SmarTrend(R) - Wed Jul 30, 4:44PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 6 months, Vivus has returned 40.89% as of today's recent price of $5.11.

The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flooring Market to Hit $255 Billion by 2031: What's Driving This?

The Construction Wave Lifts Flooring High Feels like flooring is set to ride a massive wave in the construction boom—an ambitious $255.35 billion splash by 2031. It's not the kind of climb you see out of nowhere; it’s paved by a 4.17% CAGR from 2026. This growth screams opportunity for anyone knee-deep in the construction game, where every square inch needs flooring....

Cell Counting Market Growth: USD 17.71 Billion by 2031

The Cell Counting Surge: Money Talks in Science You can't deny it when the numbers speak—a jump from USD 12.39 billion to USD 17.71 billion by 2031 in the cell counting market means something ain't business as usual. That's a robust 7.40% CAGR folks; it's a field being bombarded with innovation. The spark? Automated and advanced cell analysis technology taking the...

Trimble Revamps SketchUp: Game-Changing Design Innovations

Breaking Down Trimble's Latest Moves in Design Software The design world spins on innovation, and Trimble's pushing the boat out with SketchUp 2027. Unveiled at the swanky Trimble Dimensions User Conference in Las Vegas, this revamp is all about smashing through workflow barriers that have tripped up designers for too long. If you've ever haggled with clunky model...

Call for Biotech Shift: Scarcity Drives Urgency

The Cry for an Industrial Biotech Shift Alright, folks, here's the deal: James Michael Matthew is waving a red flag. He's saying it's time to overhaul our approach to industrial biotechnology. Why? Because we're up against some big-time raw material shortages. Matthew's call isn't just a whisper in the wind; it's a siren echoing through an industry teetering on the edge...

Illinois's Able UP Redefines Disability Savings

A New Chapter for Disability Savings in Illinois Forget the PR gloss, folks—this is about putting more green in the pockets of folks who really need it. Illinois Treasurer Michael Frerichs is giving the state's disability savings program a serious makeover, rebranding it as Able UP and slicing the fees like a seasoned chef with a bad attitude. More Than Just a Name...

Innovative Sun Visor Tackles Trucking's Glare Issue

Shedding Light on Glare-Free Trucking Ever tried squinting your way down the highway with the sun blinding you through that annoying gap in your visor? Ask any trucker, and they'll tell you that battling glare isn't just about comfort, it's about staying safe and alert. Enter the new patent-pending invention out of Dallas that's here to address this gnawing issue—the...

Fields Law Firm Rallies for Toy Donations This Season

Community Spirit Kicks Off at Fields Law Firm It’s always a bright idea when companies open their doors for a good cause, especially when it involves spreading cheer to children. Over in Minnetonka, Fields Law Firm is doing just that as they jump into the holiday spirit by collecting toys for Toys for Tots through December 11. It’s a chance for everyone to get...

TIER IV Unveils Open-Source AI Models for Autonomous Cars

End-to-End AI: Revolution at TIER IV Well, folks, TIER IV is shaking things up in the world of autonomous driving. They've just rolled out a bunch of end-to-end (E2E) AI models under the open-source banner of Autoware. Each model is designed to adapt to different map and sensor setups. You know, it’s like they're handing the keys of customization to developers—whether...

Mather Promotes Connection with Free Gardening Kits

Winter Loneliness No Match for Mather’s Green Thumb Initiative Here's something heartfelt coming out of the Windy City: gardening kits. This ain't your standard Wall Street babble—it's about a nonprofit called Mather trying to shed some light on the colder months by giving seniors in Illinois a damn good reason to be joyfully busy. No boilersuit and tie needed, just a...

Otus Earns Top Spot in Education AI at Innovation Awards

Acknowledging AI's Growing Role in Education Times are changing, and the classroom ain't what it used to be. Enter Otus, a platform that's breaking the mold by bringing artificial intelligence smack dab into K-12 education. They've bagged the 2026 SmartBrief Innovation Award in AI within the Education category. Clocking in at serving nearly 100 school districts, it's...